Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
AssigneeScience & Technology Corporation @ UNM
InventorsWalter Kisiel, Hitendra Chand
Life of this patent
Estimating the term…
Abstract
A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2).
Claims51
A polypeptide consisting essentially of a primary structure that is similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2), with the proviso that said polypeptide includes a lysine instead of arginine at position 24 as defined for the wild-type KD1 amino acid sequence.
A polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide.
A method for treating a subject for a condition treatable by aprotinin, said method comprising administering to the subject an effective amount of a polypeptide consisting essentially of a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2).
A method for treating a subject for a condition treatable by aprotinin, said method comprising administering to the subject an effective amount of a polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide.
A method for treating a subject afflicted with allergies or asthma, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2).
A method for treating a subject afflicted with allergies or asthma, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide.
A method for treating a subject afflicted with cancer or a precancerous condition, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2).
A method for treating a subject afflicted with cancer or a precancerous condition, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide.
A method for treating a subject afflicted with an influenza infection, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2).
A method for treating a subject afflicted with an influenza infection, said method comprising administering to a subject an effective amount of a polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide.
A method for treating a subject in need of surgery comprising administering an effective amount of a polypeptide consisting essentially of a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2) to the subject before, during and/or after surgery.
A method for treating a subject in need of surgery comprising administering an effective amount of a polypeptide consisting essentially of:
- a KD1 domain having a primary structure that is equivalent to or similar to the primary structure of the wild-type KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2) (SEQ ID NO:2);
- and
- a multiply positively charged amino acid sequence disposed at either or both of the N-terminal or C-terminal end of the polypeptide to the subject before, during and/or after surgery.
Dependencies are inferred from the claim text.